Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060123 | 1.00 | IKBKB (1.00) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL5195648 | 0.85 | IKBKB (0.74) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL30972572 | 0.85 | IKBKB (0.74) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL29538 | 0.81 | IKBKB (0.69) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL2099350 | 0.81 | IKBKB (0.69) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL28239861 | 0.81 | IKBKB (0.68) | IKBKBALDH1A1KDM4EGAAGLA | |
| SCHEMBL31301 | 0.80 | IKBKB (0.67) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL22388 | 0.80 | IKBKB (0.67) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL7673682 | 0.80 | IKBKB (0.67) | IKBKBALDH1A1KDM4EGAAHPGD | |
| SCHEMBL1723156 | 0.80 | IKBKB (0.67) | IKBKBALDH1A1KDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2022-01-06 | — | — | US | disclosed |
| US-11130736-B2 | Human TLR8-selective agonists | UNIVERSITY OF KANSAS (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3337481-B1 | QUINOLINE-2-AMINE DERIVATIVES AS HUMAN TLR8-SELECTIVE AGONISTS FOR INCREASING IMMUNE RESPONSE | UNIV KANSAS (US) | 2020-11-11 | — | — | EP | disclosed |
| CN-106699755-B | A kind of aza-acridine class compound and preparation method thereof and purposes | 清华大学深圳研究生院 | 2018-09-21 | — | — | CN | disclosed |
| US-20180258045-A1 | HUMAN TLR8-SELECTIVE AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-13 | — | — | US | disclosed |
| EP-3337481-A1 | HUMAN TLR8-SELECTIVE AGONISTS | The University of Kansas (US) | 2018-06-27 | — | — | EP | disclosed |
| CN-106699755-A | Aza-acridine compound and preparation method and application thereof | 清华大学深圳研究生院 | 2017-05-24 | — | — | CN | disclosed |
| CN-106699755-A | Aza-acridine compound and preparation method and application thereof | 清华大学深圳研究生院 | 2017-05-24 | — | — | CN | disclosed |
| WO-2017034986-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-1968944-B1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2016-04-20 | — | — | EP | disclosed |
| WO-2000064877-A1 | 2-AMINOQUINOLINECARBOXAMIDES: NEUROKININ RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
| US-5908930-A | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors | PFIZER INC. (US) | 1999-06-01 | — | — | US | disclosed |
| CN-1169986-A | 2.9-diamino-and 2-amino-8-carbamoyl-4-hydroxy-aldanoic acid amide derivatives | CIBA GEIGY AG (CH) | 1998-01-14 | — | — | CN | disclosed |
| WO-1996028444-A1 | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5442070-A | Derivatives of fluoro-quinoline carboxylic-3-acid and preparation therefor | LABORATOIRE ROGER BELLON (FR) | 1995-08-15 | — | — | US | disclosed |
| US-4134981-A | ANTIALLERGENS | PFIZER INC. (US) | 1979-01-16 | — | — | US | disclosed |
| US-4120962-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4044134-A | FUSED WITH QUINOLINE OR PYRIDINE, 2-METHYL, ETHYL, OR ACETYL GROUP | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-4011324-A | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents | PFIZER INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3974161-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130736-B2 | Human TLR8-selective agonists | TLR7, TLR8, TLR9 | IKBKB 1385/4885ALDH1A1 4003/4885KDM4E 2507/4885 |
| US-20180258045-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | IKBKB 1385/4885ALDH1A1 4003/4885KDM4E 2507/4885 |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | IKBKB 1385/4885ALDH1A1 4003/4885KDM4E 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.